Is RGNX research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RGNX. It does not provide personalized investment advice.

RGNX (REGENXBIO Inc.) Stock Analysis - Financials

REGENXBIO Inc. (RGNX) is a publicly traded Healthcare sector company. As of July 5, 2026, RGNX trades at $13.28 with a market cap of $686.54M and a P/E ratio of -2.37. RGNX moved +1.38% today. Year to date, RGNX is -5.75%; over the trailing twelve months it is +54.06%. Its 52-week range spans $5.04 to $16.19. Analyst consensus is strong buy with an average price target of $20.89. Rallies surfaces RGNX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What are RGNX's key financials?

RGNX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RGNX recently traded at $13.28. Market cap is $686.54M. P/E ratio is -2.37. Revenue is $87.82M.

RGNX Key Metrics

Key financial metrics for RGNX
Metric	Value
Price	$13.28
Market Cap	$686.54M
P/E Ratio	-2.37
EPS	$-5.60
Dividend Yield	0.00%
52-Week High	$16.19
52-Week Low	$5.04
Volume	0
Avg Volume	0
Revenue (TTM)	$87.82M
Net Income	$-290.01M
Gross Margin	0.00%

RGNX Analyst Consensus

9 analysts cover RGNX: 0 strong buy, 8 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $20.89.

Common questions about RGNX

What are RGNX's key financials?: RGNX financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. RGNX recently traded at $13.28. Market cap is $686.54M. P/E ratio is -2.37. Revenue is $87.82M.
Is RGNX research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RGNX. It does not provide personalized investment advice.